Probucol Derivative Design for Enhanced Bioavailability and Reduced QT Prolongation

The patent modifies the chemical structure of probucol by introducing polar groups (carboxyl, hydroxyl, amino groups) and adjusting the substitution patterns on the phenolic rings. These structural parameter changes increase water solubility while preserving the core antioxidant mechanism. Specifically, compounds with carboxymethyl and hydroxymethyl substitutions show improved aqueous solubility compared to the parent probucol molecule.

The patent designs derivatives that simultaneously target multiple metabolic pathways. The modified probucol compounds exhibit dual functionality: maintaining antioxidant protection against atherosclerosis while enhancing glucose and lipid metabolism regulation. This is achieved through structural modifications that allow interaction with multiple biological targets, including insulin signaling pathways and lipid metabolism enzymes.

The patent introduces specific local modifications to the probucol structure, such as adding polar substituents at particular positions on the aromatic rings. These localized changes alter the drug's interaction with cardiac ion channels, reducing QT prolongation effects while preserving the cardioprotective antioxidant activity. The modifications are strategically placed to minimize off-target effects on cardiac electrophysiology.

The patent creates chemically modified composite structures based on the probucol scaffold. By combining the hydrophobic aromatic core with hydrophilic substituents (carboxymethyl, hydroxymethyl, amino groups), the derivatives achieve a balance between membrane permeability and aqueous solubility. This composite molecular architecture improves bioavailability while maintaining the anti-inflammatory properties of the original compound.